Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    New Drug Regimen Shows Promising Results for Advanced Biliary-Tract Cancers - (DGNews)
    Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12 - (JAMA)
    Treatment With Folic Acid, Vitamin B12 Associated With Increased Risk of Cancer, Death - (DGNews)
    Glans Resurfacing With Split-Thickness Skin Graft Helps Manage Benign and Malignant Conditions: Presented at ESSM - (DGDispatch)
    HDL Cholesterol Inversely Associated With Cancer Risk: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
      Non-AIDS-Defining Cancers in Patients with HIV Infection
      Carcinoid Tumors of the Gastrointestinal Tract
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Multidisciplinary Approach to Management of Neuroendocrine Tumors
      Cancer and Venous Thromboembolism: Current Clinical Issues

      Webcasts/CME archive

       Recent cases - Oncology Other
        Jejuno-Jejunal Invagination Caused by Epithelioid Sarcoma: A Case Report
        Thoracic Spinal Cord Compression Caused by Metastatic Pheochromocytoma
        Osseous Hemangioma of the Seventh Cervical Vertebra with Osteoid Formation Mimicking Metastasis: A Case Report
        Hypercalcemia in a Patient with Cholangiocarcinoma: A Case Report
        Difficult Diagnosis of Brainstem Glioblastoma Multiforme in a Woman: A Case Report and Review of the Literature

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Cisplatin Plus Gemcitabine Appears Active Against Advanced Gastric Cancer

        A DGReview of :"Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer"
        Annals of Oncology

        04/13/2004
        By Jill Taylor


        A combination regimen of cisplatin-gemcitabine appears to have moderate efficacy in patients with unresectable gastric cancer, with myelosuppression being the most frequently occurring side effect, Dutch researchers have found.

        Additive and synergistic effects of gemcitabine and cisplatin in combination have been demonstrated in several preclinical trials. To test the combination for advanced gastric cancer, S. M. De Lange of the Department of Medical Oncology, VU University Medical Centre, Amsterdam, and colleagues performed a phase 2 study of 40 chemo-naive patients.

        All patients had measurable locoregionally advanced or metastatic gastric cancer. Treatment consisted of cisplatin 50 mg/m2 administered by intravenous (i.v.) infusion over 1 hour on days 1 and 8, followed after 24 hours by gemcitabine 800 mg/m2 administered by i.v. infusion over 30 minutes on days 2, 9 and 16. Chemotherapy cycles were repeated every 4 weeks. A total of 177 chemotherapy cycles were administered, with a median of 4 cycles.

        Treatment response was observed after a median of 2 cycles. At the first evaluation, 24 patients had stable disease and 6 patients had progressive disease.

        The overall objective response rate was 30%, with 2 complete remissions and 10 partial remissions. The median duration of response was 5 months, the median time to progression was 7 months, and the median survival was 11 months.

        Thirty-five patients died, 34 due to malignant disease and 1 because of a perforation that occurred during endoscopy resulting in sepsis. A significant difference in survival was found between patients with stable disease and patients with progressive disease (11 vs. 4 months; P < .00001).

        Toxicity was substantial, with myelotoxicity causing omission of gemcitabine on day 16 in 55% of cycles. Grade 3-4 thrombopaenia was observed in 48% of patients and grade 3-4 leucopaenia was observed in 58%. Grade 1-2 nausea and vomiting were the primary non-haematological toxicities.

        While the study confirmed the activity of the cisplatin-gemcitabine combination regimen in gastric cancer patients, the investigators point out that managing the toxicity of the schedule appeared challenging.

        "This and other studies underline the difficulties in identifying novel agents with activity in this disease and the increased toxicity of regimens with more than two agents," they said.






        Ann Oncol 2004 Mar;15:3:484-8. "Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send